Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.X-Chem, Bayer expand drug discovery collaboration
The expanded partnership could generate up to $528m for X-Chem. The companies agreed to extend Bayer's access to X-Chem’s DEX technology which is based on DNA-encoded libraries of
The expanded partnership could generate up to $528m for X-Chem. The companies agreed to extend Bayer's access to X-Chem’s DEX technology which is based on DNA-encoded libraries of
The parties did not disclose financial details about the collaboration, under which they will find alternative means of treating infections that are resistant to existing antibiotics. The ARBs
The regulator’s decision was based on a proposed pediatric sub-study nested within the ongoing phase 2 trial of ABT-414 in adults with recurrent epidermal growth factor receptor (EGFR)-amplified
The parties did not disclose the terms of the transaction, which is subject to customary closing conditions. The deal is expected to close in the next few months.
The combination of sofosbuvir and velpatasvir (SOF/VEL) for 12 weeks can now be used in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and in combination with
Bosutinib was earlier available only via the Cancer Drugs Fund (CDF). It is the first drug to go through the reappraisal process, where NICE evaluates the cost and
The study’s objective was to investigate the safety and efficacy of several dose regimens for vobarilizumab monotherapy to support additional clinical development. Its primary endpoint was the proportion
The Egality trial focused on patients with moderate-to-severe chronic plaque-type psoriasis. The European Medicines Agency and the US Food and Drug Administration accepted for regulatory review of Sandoz
Adcetris, which is being jointly developed by Seattle Genetics and Takeda, is now approved for marketing of this indication in the 28 member states of the European Union,
Under the three-year research collaboration, the companies will explore the use of mRNA Therapeutics to treat the prime cause of CF by allowing cells to produce functional CFTR